Wockhardt partners with RDIF to produce, supply Sputnik vaccine

By: |
Updated: August 13, 2021 4:19 PM

The agreement has been inked under the aegis of Enso Healthcare (part of Enso Group), RDIF's coordination partner for sourcing Sputnik V vaccines in India.

Drug maker Wockhardt, Russian Direct Investment Fund, Enso Healthcare, Sputnik V, Sputnik Light vaccines, vaccination of the populationThe term of the agreement is up to June 2023

Drug maker Wockhardt on Friday said it has inked a pact with the Russian Direct Investment Fund (RDIF) to produce and supply COVID-19 vaccines — Sputnik V and Sputnik Light. The agreement has been inked under the aegis of Enso Healthcare (part of Enso Group), RDIF’s coordination partner for sourcing Sputnik V vaccines in India.

“We are delighted to partner with RDIF to make a substantial contribution towards providing global supply of the Sputnik V and Sputnik Light vaccines which is one of the most efficacious approved vaccines commercially available,” Wockhardt Group Founder Chairman Habil Khorakiwala said in a statement. The arrangement upholds the company’s ongoing commitment to fight against such a pandemic of global human importance, he added.

“It is our privilege to partner with RDIF and Wockhardt to facilitate large scale manufacturing of Sputnik V and Sputnik Light vaccines,” Enso Healthcare Chairman Vinay Maloo noted. In a regulatory filing, Wockhardt noted that subject to requisite approvals and other conditions, the company would manufacture and supply up to 620 million doses of the Sputnik V and the Sputnik Light vaccines to Enso. The term of the agreement is up to June 2023, it added.

Till date, the Sputnik V vaccine has been registered in 69 countries globally with a total population of over 3.7 billion people. The data obtained by regulators of a number of countries during the vaccination of the population, including Argentina, Serbia, Bahrain, Hungary, Mexico, San Marino, UAE and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.

In particular, Sputnik V demonstrates 83.1 per cent efficacy against the Delta variant of coronavirus – higher than many other vaccines. The vaccine is based on a well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

Sputnik Light is the first component of Sputnik V and is based on human adenovirus serotype 26. Wockhardt shares were trading 4.92 per cent up at Rs 513.35 apiece on BSE

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Novavax, SII apply to WHO for emergency use listing of COVID vaccine
2Not many places left for COVID-19 virus to evade immunity: UK vaccine creator
3India’s vaccination figure crosses 84 crore doses